# **Technical Data Sheet**

# **Purified Mouse Anti-Human CD253**

### **Product Information**


Material Number:550515Size:0.1 mgConcentration:0.5 mg/mlClone:RIK-2Immunogen:Human TRAILIsotype:Mouse IgG1Reactivity:QC Testing: Human

Storage Buffer: Aqueous buffered solution containing ≤0.09% sodium azide.

### Description

TRAIL (TNF-Related Apoptosis-Inducing Ligand), also known as Apo2L, is a member of the TNF ligand family. TRAII is a type II membrane protein which may be expressed as a full-length, cell surface associated protein as well as in a soluble form. Both surface and soluble forms of TRAIL rapidly induce apoptosis on a wide range of cell lines. TRAIL has been shown to cause apoptotic death in either tumorigenic or transformed cells, but not in normal cells. TRAIL-mediated apoptosis has been shown to involve the activation of caspases, and is blocked by over-expression of the caspase-1 protease inhibitor, CrmA. TRAIL has also been reported to induce the transcription factor NF-kB in a cell type-specific manner. Two cognate TRAIL receptors DR4, and DR5, as well as two decoy receptors, DcR1/TRID and DcR2/TRUNDD have been identified. TRAIL has been shown to be involved in T cell cytotoxicity, but the exact physiological role TRAIL plays in T-cell mediated cytotoxicity remains to be elucidated.

The RIK-2 antibody recognizes human TRAIL. Human TRAIL cDNA was transferred to an expression vector and transfected into the 2PK-3 mouse B cell lymphoma cell line to generate stable transfectants, which were then used to immunize mice. The RIK-2 clone was selected based on its ability to block cytotoxic activity. TRAIL has been renamed as CD253 recently.



Flow cytometric analsis of TRAIL. Profile of human TRAIL/2PK-3 cell line analyzed on a FACScan™ (BDIS, San Jose. CA).

#### **Preparation and Storage**

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. Store undiluted at  $4^{\circ}$ C.

## **Application Notes**

Application

Flow cytometry Routinely Tested

# **Recommended Assay Procedure:**

## **Recommended Assay Procedure:**

Immunofluorescent Staining and Flow Cytometry: Applications include flow cytometry (0.25-1.0 μg/1x10e6 cells).

### **BD Biosciences**

bdbiosciences.com

 United States
 Canada
 Europe
 Japan
 Asia Pacific
 Latin America/Caribbean

 877.232.8995
 888.259.0187
 32.53.720.550
 0120.8555.90
 65.6861.0633
 55.11.5185.9995

For country-specific contact information, visit <code>bdbiosciences.com/how\_to\_order/</code>

Conditions: The information disclosed herein is not to be construed as a recommendation to use the above product in violation of any patents. BD Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton Dickinson and Company is strictly prohibited. For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.

BD, BD Logo and all other trademarks are the property of Becton, Dickinson and Company. ©2008 BD



550515 Rev. 4 Page 1 of 2

**Blocking**: The RIK-2 antibody is useful to block TRAIL-induced apoptosis. The no azide/low endotoxin format (NA/LE), Cat. No. 550912, is recommended for in vitro blocking assays.

## **Suggested Companion Products**

Catalog Number	Name	Size	Clone
553141	Purified Rat Anti-Mouse CD16/CD32 (Mouse BD Fc Block <sup>TM</sup> )	0.1 mg	2.4G2

#### **Product Notices**

- 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- 2. Please refer to www.bdbiosciences.com/pharmingen/protocols for technical protocols.
- 3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.

## References

Kayagaki N, Yamaguchi N, Nakayama M, et al. Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. *J Immunol.* 1999; 162(5):2639-2647.(Immunogen: Blocking)

Mariani SM, Matiba B, Armandola EA, Krammer PH. Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. *J Cell Biol.* 1997; 137(1):221-229.(Biology)

Marsters SA, Pitti RM, Donahue CJ, Ruppert S, Bauer KD, Ashkenazi A. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr Biol. 1996; 6(6):750-752.(Biology)

Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. *J Biol Chem.* 1996; 271(22):12687-12690.(Biology)

Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. *Science*. 1997; 277(5327):818-821. (Biology)

Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. *Immunity*. 1995; 3(6):673-682.(Biology)

550515 Rev. 4 Page 2 of 2